Several specific or nonspecific serological biomarkers can be found in advanced melanoma patients.9 LDH as well as S100B serum levels have been correlated with poor prognosis in AJCC stage III–IV melanoma patients3; however, the poor sensitivity and specificity of those markers limit their use in early melanoma patients (AJCC stage I–II). The gene discussed is S100B; the disease is melanoma.